Sun. May 9th, 2021


Radiation exposure in Cath labs remains a concern: Sanjay David, Head of Advanced Therapies, Siemens HealthineersShahid Akhter, editor, ETHealthworld spoke to Sanjay David, Head of Advanced Therapies, Siemens Healthineers, to know more about the latest advancements in interventional cardiology and how robotics are destined to play a big role.

Role Siemens Healthineers plays in the field of cardiology – especially in the field of Interventional cardiology?
Around the world, cardiovascular diseases are the leading cause of death. To increase life expectancy for patients suffering from cardiovascular diseases, our solutions address the entire continuum of care with a precise diagnosis, personalized therapy, and continuous follow-up.

With excellent image quality in different modalities to having lab test results right at your fingertips, our connected cardiovascular solutions ensure patient focus approach throughout the entire clinical pathway. We easily integrate third-party systems into the cardiovascular network with our dedicated Cardiovascular IT. As a partner for holistic cardiovascular care, we are committed to supporting in improving patient outcomes – by transforming care delivery and expanding precision medicine through digitalizing healthcare.

Radiation exposure in Cath labs remains a concern. We provide excellent image quality and lowest possible radiation impact for patient and staff. Therefore, putting together one of the most future-oriented portfolios in cardiology, with smart solutions designed to set new standards of care, safety and efficiency for the patients and healthcare professionals.

How acquisition of Corindus complements Siemens Healthineers offerings?
Siemens Healthineers completed the acquisition of Corindus Vascular Robotics, Inc. effective October 29, 2019 and the integration is now completed. Siemens Healthineers is now offering the sales and service facilities for Corindus CorPath GRX Intravascular Robots, in India.

The combination of Siemens Healthineers’ strong medical technology portfolio with its digital platforms and solutions, along with Corindus’ precision robotics platform, has the potential to transform healthcare delivery, providing an opportunity to patients for better care at lower cost.

Corindus is the first company in the world to provide a precision robot to treat vascular conditions like blocked arteries. It is the First company offering a robot which is FDA cleared and CE marked for all interventional procedures in Percutaneous Coronary Intervention (PCI) and Peripheral Vascular Intervention (PVI). This technology assists the doctors in performing complex procedures, with smart procedural automation, thus, empowering the hands of the cardiologists.

The precision robotic technology, designed to enhance visualization and protect the operator against exposure to radiation and other occupational hazards such as eye and back strain, it supports the cardiologist through the procedure for better clinical outcomes.

How robotics is adding value and impacting healthcare in India?
Generally, robotics enables precision care delivery to the patients. However, currently, the robotic technology in India is focused on improving surgical outcomes. Corindus CorPath GRX Intravascular Robot introduced by Siemens Healthineers is the first robot in the intravascular arena. This unique robot protects the physician and facilitates the reduction of radiation dose to the patient by 20%. Additionally, it significantly increases the ability of the doctors to perform complex procedures with precision and standardization.

The system provides control of the procedure from an interventional cockpit, allowing precise, robotic-assisted positioning of coronary guide catheters, guidewires, and balloon/stent catheters. The physician can operate from a comfortable environment, completely focusing on the patient.

The robotics technology offers the following benefits:

For patients:

    • Reduces radiation by up to 20%,
    • Brings in improvement towards optimal stent deployment by upto 8%
    • Ensures a shorter procedural time for complex procedures.

For doctors:

  • Reduces risk of occupational hazards while operating inside the examination room of the Cath lab every day.
  • Wearing heavy lead apron as protection from radiation is completely obviated by the Corindus CorPath GRX, as it allows performing the procedure from a remote console without the necessity of wearing any lead apron.
  • Smart procedural automation enhances the ability of the cardiologists to perform complex procedures reliably and efficiently. Sub millimeter measurement allows very accurate selection of stents.

For hospitals:

  • CorPath GRX robot brings better clinical outcomes for the patients which helps reinforce the brand of the hospital.
  • Operations performed with CorPath GRX in India

Padmashri Dr. Tejas Patel, Chairman and Chief Interventional Cardiologist, Apex Heart Institute, Ahmedabad, India is one of the most experienced users of CorPath GRX in the world, having done more than 500 robotic procedures.

The first in-human long distance, tele robotic procedure was demonstrated by Dr. Patel using the Corindus CorPath GRX robot. Dr. Patel operated the robot from a place 32 kms away from the Cath lab and successfully performed PCI on five patients ranging from 50 to 80 years of age. This opened the possibility of remote treatment for patients, overcoming the geographical and resource barriers of limited hospitals with these facilities and especially skilled professionals to perform complex procedures.

Apollo Hospitals, Chennai and Magnus Heart Hospital, Nashik are also using the CorPath GRX robot in India.

Future of robotics in the cardiology?
The Indian healthcare industry started embracing surgical robotics during the mid-2000s. Increase in the number of surgical robots from six in 2009 to around 100 in 2019 has helped to shape up the domestic market for surgical robotics. The CorPath GRX is the first intravascular robot introduced in India.

For certain procedures, such as heart attack and stroke, time is of the essence. Any delay in treatment can have a negative impact on outcomes for patients. However, due to the lack of skilled specialists and facilities that can perform the gold standard of treatment, less than 10% of eligible patients receive this treatment in time and rates of death and disability are staggeringly high.

The robotic interventions can significantly contribute to cardiovascular medical conditions like heart diseases, where the ideal treatment include complex procedures by specialized medical professionals only.

Possibilities of remote treatment in the near future will address the key geographical challenges of limited availability of specialists and corresponding clinical facilities for minimally invasive procedures in many regions.

Our aim is to bring the physicians to the patients through telerobotics to enable treatment for increased number of patients, in a shorter window of time.

Adoption of robotics in surgical intervention will provide enormous impetus to the Indian healthcare sector and more so in the field of cardiovascular interventions.





Source link